Home / Market News / $ALC

$ALC news and market catalysts

The 15 most recent market catalysts affecting $ALC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 6 high impact 8 bullish 4 bearish Healthcare
Nov 11, 2026 Corporate Catalyst Bearish Impact 92
Alcon Reports Q3 2026 Financial Results and Narrows Full-Year Guidance
Alcon announced Q3 2026 financial results that fell short of analyst expectations, with net sales of $2.72 billion versus an anticipated $2.73 billion. This miss was attributed to …
Nov 2, 2026 Corporate Catalyst Bearish Impact 55
AlphaValue/Baader Europe Downgrades Alcon to Add
Financial services firm AlphaValue/Baader Europe has downgraded Alcon's stock rating from an unspecified higher rating to 'Add'. This action signifies a less optimistic outlook fro…
Oct 20, 2026 Corporate Catalyst Neutral Impact 92
Alcon Acquires Neurotech Pharmaceuticals For $550M
Alcon has acquired Neurotech Pharmaceuticals for $550 million, with potential for additional contingent payments. This acquisition is significant because it brings ENCELTO, the fir…
Oct 16, 2026 Corporate Catalyst Bullish Impact 65
Alcon Announces FDA Approval For BRYTLY Redness Relief Eye Drops, Expanding Over The Counter Eye Care Portfolio.
Alcon has secured FDA approval for BRYTLY Redness Relief Eye Drops, a new over-the-counter product that promises up to 12 hours of redness relief, outperforming a key competitor, L…
Oct 12, 2026 Corporate Catalyst Bearish Impact 55
BTIG Maintains Buy on Alcon, Lowers Price Target to $74
BTIG analyst Ryan Zimmerman reaffirmed a 'Buy' rating for Alcon, signaling continued confidence in the company's long-term prospects. However, the simultaneous reduction of the pri…
Oct 7, 2026 Corporate Catalyst Neutral Impact 55
Barclays Initiates Coverage On Alcon with Equal-Weight Rating, Announces Price Target of $70
Barclays has initiated coverage on Alcon (ALC) with an 'Equal-Weight' rating and a $70 price target. This event is significant as new analyst coverage, especially from a major inst…
Sep 1, 2026 Corporate Catalyst Bullish Impact 65
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
President Trump has expanded his drug pricing initiative, securing agreements with nine additional pharmaceutical companies, bringing the total to 26. These agreements mandate disc…
Aug 19, 2026 Corporate Catalyst Neutral Impact 75
Reported Earlier, Alliance Laundry Prices Upsized Offering Of 22.55M Common Shares By Selling Stockholder BDT Capital Partners At $23.50 Per Share
The upsized offering of 22.55 million common shares by BDT Capital Partners at $23.50 per share for Alliance Laundry (ALC) is a significant corporate catalyst. While the upsized na…
Aug 12, 2026 Corporate Catalyst Bullish Impact 55
Mizuho Maintains Outperform on Alcon, Raises Price Target to $85
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on Alcon and raised the price target from $80 to $85. This action signals increased confidence from a reputable fin…
Aug 11, 2026 Corporate Catalyst Bullish Impact 55
Needham Maintains Buy on Alcon, Raises Price Target to $98
Needham analyst David Saxon maintained a 'Buy' rating on Alcon and raised the price target from $95 to $98. This action signals continued confidence in Alcon's business fundamental…
Aug 11, 2026 Corporate Catalyst Bullish Impact 85
Alcon shares are trading higher after the company reported better-than-expected Q2 financial result and raised its FY26 adjusted EPS guidance above estimates. Also, the company widened its FY26 sales guidance.
Alcon's better-than-expected Q2 results and raised FY26 guidance are a significant positive catalyst, directly impacting its stock price upwards. This indicates strong underlying b…
Aug 10, 2026 Corporate Catalyst Bullish Impact 85
Alcon shares are trading higher after the company reported better-than-expected Q2 financial result and raised its FY26 adjusted EPS guidance above estimates. Also, the company widened its FY26 sales guidance.
Alcon's strong financial performance, particularly the raised FY26 EPS and sales guidance, indicates strong demand for its products and effective cost management. This positive cor…
Aug 10, 2026 Corporate Catalyst Bullish Impact 92
Alcon Q2 Adj. EPS $0.84 Beats $0.75 Estimate, Sales $2.782B Beat $2.769B Estimate
Alcon's Q2 earnings report shows a significant beat on both adjusted EPS and sales estimates. The adjusted EPS of $0.84 surpassed the $0.75 consensus by 12%, and sales of $2.782 bi…
Aug 7, 2026 Corporate Catalyst Bullish Impact 85
Algoma Central Q2 EPS $0.88 Beats $0.78 Estimate, Sales $258.273M Miss $2.770B Estimate
Algoma Central reported Q2 earnings that beat analyst consensus, but this positive was overshadowed by a massive sales miss, falling short of estimates by over 90%. While EPS grew …
Jul 15, 2026 Corporate Catalyst Bearish Impact 55
Mizuho Maintains Outperform on Alcon, Lowers Price Target to $80
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on Alcon, signaling continued confidence in the company's fundamentals and long-term growth prospects. However, the…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.